Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa

EMERYVILLE, Calif.–(BUSINESS WIRE)–Octant, Inc. (“Octant”), a clinical-stage drug discovery company developing correctors for protein misfolding diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to OCT-980 for the treatment of retinitis pigmentosa (RP). The designation includes rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), the indication for which OCT-980 is currently being developed.OCT-980 is an investiga